November 14, 2024, saw the acceptance for review by the National Medical Products Administration of another new product developed by Genecradle Therapeutics—GC310 adeno-associated virus (AAV) injectio

From November 4th to 6th, 2024, a delegation from Beijing Genecradle Therapeutics Technology Co., Ltd. traveled to Stockholm, Sweden, to attend the highly anticipated 2024 BIO-Europe Autumn Conference.

On October 18, 2024, Secretary Zhang Qiang of the Working Committee of Beijing E-Town visited Beijing Genecradle Therapeutics Technology Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics"

A phase I clinical trial titled "Evaluation of the Safety and Tolerability of GC304 Adeno-Associated Virus Injection in Patients with Primary Hypertriglyceridemia and a History of Acute Pancreatitis"

Professor Wu Xiaobing Invited to the China Women Physicians Conference and Elected as a Member of the Rare Disease Professional Committee

Recently, Genecradle Therapeutics' GC301 adeno-associated virus (AAV) injection for the treatment of late-onset Pompe disease (LOPD) has successfully completed the first intravenous dosing in a gene t

Recently, in the "13th China Innovation and Entrepreneurship Competition Beijing Regional Biomedical Industry Competition and the 9th Beijing Innovation and Entrepreneurship Biomedical and Artificial

On July 10, 2024, the Phase I/II clinical trial kick-off meeting for the treatment of type 3 spinal muscular atrophy (SMA) patients with GC101 adeno-associated virus injection, an AAV gene therapy dru

The Global Cell & Gene Therapy Summit 2024 (CGT Summit 2024) was held as scheduled in Boston, the United States from July 8 to 10, 2024. The summit brought together pharmaceutical companies and re